These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9115051)

  • 1. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics.
    Karim A; Noveck R; McMahon FG; Smith M; Crosby S; Adams M; Wilton J
    J Clin Pharmacol; 1997 Apr; 37(4):267-78. PubMed ID: 9115051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.
    Karim A
    J Clin Pharmacol; 1996 Nov; 36(11):985-97. PubMed ID: 8973987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of oxaprozin.
    Davies NM
    Clin Pharmacokinet; 1998 Dec; 35(6):425-36. PubMed ID: 9884815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaprozin disposition in renal disease.
    Chiang ST; Morrison G; Knowles JA; Ruelius HW; Walker BR
    Clin Pharmacol Ther; 1982 Apr; 31(4):509-15. PubMed ID: 7060332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics.
    Audet PR; Knowles JA; Troy SM; Walker BR; Morrison G
    Clin Pharmacol Ther; 1988 Sep; 44(3):303-9. PubMed ID: 3416552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen.
    Scavone JM; Ochs HR; Greenblatt DJ; Matlis R
    Eur J Clin Pharmacol; 1988; 35(1):105-8. PubMed ID: 3220091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaprozin pharmacokinetics in the elderly.
    Greenblatt DJ; Matlis R; Scavone JM; Blyden GT; Harmatz JS; Shader RI
    Br J Clin Pharmacol; 1985 Mar; 19(3):373-8. PubMed ID: 3986088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug.
    Miller LG
    Clin Pharm; 1992 Jul; 11(7):591-603. PubMed ID: 1617910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.
    Rudy AC; Figueroa NL; Hall SD; Brater DC
    Br J Clin Pharmacol; 1994 Jan; 37(1):1-5. PubMed ID: 8148211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piroxicam immediate release formulations: A fasting randomized open-label crossover bioequivalence study in healthy volunteers.
    Helmy SA; El-Bedaiwy HM
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):466-71. PubMed ID: 27129120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant?
    Scharf S; Kwiatek R; Ugoni A; Christophidis N
    Aust N Z J Med; 1998 Aug; 28(4):436-9. PubMed ID: 9777110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of age on the pharmacokinetics of tenoxicam in comparison to other non-steroidal anti-inflammatory drugs (NSAIDs).
    Schmitt M; Guentert TW
    Scand J Rheumatol Suppl; 1989; 80():86-9. PubMed ID: 2688082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaprozin dose proportionality.
    Chiang ST; Lasseter KC; Fluck ER; Janssen FW; Leelavathi D; Hubsher JA
    J Clin Pharmacol; 1984; 24(11-12):515-22. PubMed ID: 6511991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.
    Brenner SS; Herrlinger C; Dilger K; Mürdter TE; Hofmann U; Marx C; Klotz U
    Clin Pharmacokinet; 2003; 42(3):283-92. PubMed ID: 12603175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.
    Scavone JM; Greenblatt DJ; Matlis R; Harmatz JS
    Eur J Clin Pharmacol; 1986; 31(3):371-4. PubMed ID: 3792438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of the multiple dose pharmacokinetics and the tolerance of a new NSAID (droxicam) versus piroxicam in healthy volunteers.
    Martínez L; Sánchez J; Roser R; García-Barbal J; Bartlett A; Estruch J; Sagarra R; Puig S; Costa A
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):729-37. PubMed ID: 3221746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and kinetics of oxaprozin in normal subjects.
    Janssen FW; Jusko WJ; Chiang ST; Kirkman SK; Southgate PJ; Coleman AJ; Ruelius HW
    Clin Pharmacol Ther; 1980 Mar; 27(3):352-62. PubMed ID: 7357792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaprozin pharmacokinetics in patients with congestive heart failure.
    Ochs HR; Greenblatt DJ; Knüchel M
    Arzneimittelforschung; 1986 Dec; 36(12):1837-40. PubMed ID: 3566846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.
    Perini JA; Vianna-Jorge R; Brogliato AR; Suarez-Kurtz G
    Clin Pharmacol Ther; 2005 Oct; 78(4):362-9. PubMed ID: 16198655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.